Bharat Parenterals Reports Record Sales Amid Significant Profit Declines in March 2025
Bharat Parenterals has announced its financial results for the quarter ending March 2025, reporting net sales of Rs 103.98 crore, a significant year-on-year increase. However, the company faced challenges with negative Profit Before Tax and Profit After Tax figures, alongside rising interest expenses, indicating increased borrowing costs.
Bharat Parenterals, a small-cap player in the Pharmaceuticals & Biotechnology sector, has released its financial results for the quarter ending March 2025. The company reported net sales of Rs 103.98 crore, reflecting a significant year-on-year growth of 53.32%. This figure marks the highest sales recorded in the last five quarters, indicating a positive near-term sales trend.However, the financial results also reveal challenges for Bharat Parenterals. The Profit Before Tax (PBT) stood at Rs -10.23 crore, showing a notable decline of 155.75% year-on-year. Similarly, the Profit After Tax (PAT) was reported at Rs -4.73 crore, which represents a drastic fall of 1476.7% compared to the previous year. Additionally, the interest expense reached its highest level in the last five quarters at Rs 3.94 crore, reflecting an increase of 18.32% quarter-on-quarter, suggesting a rise in borrowing costs.
In light of these developments, Bharat Parenterals has experienced adjustments in its evaluation, with its score improving from -10 to -7 over the past three months.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
